This article examines the significant Go-to-Market (GTM) hurdles for medical technology (MedTech) startups operating in the DACH region, which includes Germany, Austria, and Switzerland. Market entry in this territory is heavily influenced by a rigorous regulatory framework consisting of the EU Medical Device Regulation (MDR), the In Vitro Diagnostic Regulation (IVDR), and the General Data Protection Regulation (GDPR). The research identifies that these startups often struggle with internal capacity to manage such multifaceted requirements, resulting in substantial product launch delays and heightened operational costs. For example, more than 70% of German MedTech startups have reported GTM delays specifically due to bottlenecks related to the MDR. The study highlights that the MDR, enforced since 2021, introduced stricter clinical evaluation needs and mandatory engagement with notified bodies, which has strained existing capacities and doubled review timelines in some instances. To navigate these challenges, the article explores the strategic integration of management technologies. This includes the use of regulatory information management systems, quality management software, and project management tools designed to improve the efficiency and effectiveness of GTM execution. A notable real-time use case utilizes Natural Language Processing (NLP) and Large Language Models (LLMs) to automate MDR documentation, reportedly reducing compliance preparation time by 70%. Ultimately, the research suggests that by embedding regulatory milestones directly into launch roadmaps and utilizing Regulatory Technology (RegTech) solutions, MedTech startups can transform compliance from a formidable barrier into a strategic competitive advantage within the DACH region.
Abu Yusuf Mohammad Habibur Rahman (Tue,) studied this question.